Navigation Links
Takeda Announces New U.S. Leadership
Date:3/19/2008

Proposed appointments effective at conclusion of TAP transaction

DEERFIELD, Ill., March 19 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. today announced proposed new leadership for Takeda America Holdings, Inc. (TAH), Takeda Pharmaceuticals North America, Inc. (TPNA) and Takeda Global Research & Development Center, Inc. (TGRD) following an earlier announcement related to Takeda's plans to conclude its joint venture in the United States, TAP Pharmaceutical Products Inc. (TAP).

Effective at the close of the TAP transaction, Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. will report to Takeda America Holdings, Inc. Alan MacKenzie, the current president of TAP and a former president of Takeda Pharmaceuticals North America, Inc. has been named executive vice president of Takeda America Holdings.

MacKenzie will also serve as CEO of Takeda Pharmaceuticals North America, Inc. in addition to his role as executive vice president of Takeda America Holdings.

Mark Booth, current president of Takeda Pharmaceuticals North America, Inc., will continue to lead the company until the TAP transaction is closed and has agreed to continue on with the company for some period thereafter to support integration activities.

Reporting to MacKenzie as president of Takeda Global Research & Development Center, Inc. will be Nancy Joseph-Ridge, M.D., currently TAP's vice president of research and development. Dr. Joseph-Ridge will also assume her position effective the close of the TAP transaction.

"I have great confidence in Takeda's proposed new leadership for the United States, an important market for Takeda's global growth plans," said Yasuchika Hasegawa, president, Takeda Pharmaceutical Company Limited. "Alan MacKenzie not only helped launch both TPNA and its first product, Actos, he has been instrumental in helping create success at Takeda companies for more than 22 years. Dr. Nan
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Takeda submits new drug application for alogliptin (syr-322) in the US
2. Chemizon Announces Research Collaboration Expansion With Takeda
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
5. QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes
6. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
7. The Pennsylvania Breast Cancer Coalition Announces Event at the University of Pennsylvania Hospital to Celebrate the 2008 Income Tax Check-Off Campaign
8. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated
9. PRA International Announces New Office Opening in Mumbai
10. Cardiums InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems
11. Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... “Dr. Luciana Show – Aging and Falling” is ... is finding it challenging to stay on top of post-production ... hundreds of students, so the editing of the episodes will ... and she recently entered it into the festival circuit. ... husband, actor/screenwriter Gregory Graham , the aging and falling ...
(Date:8/22/2014)... Oncology (ESMO), the leading pan-European organisation representing medical ... outstanding individuals receiving the Society,s esteemed annual awards. ... Heikki Joensuu and Peter Boyle on the occasion ... Spain. , Carsten Bokemeyer will receive the ESMO ... of cancer discovery into real benefit at patient ...
(Date:8/22/2014)... Chest pain, breathing difficulties, fainting. Each year approx. 265,000 ... of serious illness. New research from Aarhus University and ... as many as every fourth patient are ... severe symptoms that led to the acute hospitalisation., "Naturally, ... examinations at the hospital disprove that there is a ...
(Date:8/22/2014)... can be slowed and some of its symptoms ... in pomegranate. Also, the painful inflammation that ... disease could be reduced, according to the findings ... Huddersfield scientist Dr Olumayokun Olajide, who specialises in ... a new phase of research can explore the ...
(Date:8/22/2014)... treated for the cancer Hodgkin lymphoma will be able ... researchers estimated their risk of premature menopause with different ... Journal of the National Cancer Institute , are based ... in England and Wales treated for the cancer over ... research has suggested that women with Hodgkin lymphoma who ...
Breaking Medicine News(10 mins):Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 3Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 4Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3Health News:Many patients are discharged without a diagnosis 2Health News:Research underway to create pomegranate drug to stem Alzheimer's and Parkinson's 2Health News:Scientists map risk of premature menopause after cancer treatment 2
... Elsevier , the world-leading publisher of scientific, technical ... Silverstein whose new book, The Initial Psychotherapy ... Award from the American Psychological Association,s Society for ... Transgender Issues. Dr. Silverstein also received a Gold ...
... Reporter , WEDNESDAY, Aug. 24 (HealthDay News) -- The percentage ... 14 percent from 22 percent in 2008, a new survey ... the September issue of Obstetrics & Gynecology , don,t ... according to those on both sides of the abortion debate. ...
... Gordon HealthDay Reporter , WEDNESDAY, Aug. ... of the antibiotic azithromycin may help prevent life-threatening ... say. These complications are commonly referred to ... doctor visits and hospitalizations. Although numerous medications are ...
... , THURSDAY, Aug. 25 (HealthDay News) -- Rheumatoid ... physical activity goals -- called self-efficacy -- are more ... The investigators also found that patients who achieve their ... and a higher quality of life. Researchers in ...
... report that patients with rheumatoid arthritis (RA) who have ... likely to achieve their physical activity goals. According to ... Research , a journal of the American College of ... with lower self-reported arthritis pain and increased health-related quality ...
... million grant from the John D. and Catherine T. ... Research Network on Law and Neuroscience. The MacArthur ... effects of modern neuroscience on criminal law and trying ... The network will be led by Vanderbilt professor Owen ...
Cached Medicine News:Health News:Elsevier congratulates Dr. Charles Silverstein upon his receipt of 2 awards 2Health News:Only 1 in 7 Ob/Gyns Now Performs Abortions, Survey Finds 2Health News:Only 1 in 7 Ob/Gyns Now Performs Abortions, Survey Finds 3Health News:Long-Term Antibiotic Use May Lessen COPD Flare-Ups 2Health News:Long-Term Antibiotic Use May Lessen COPD Flare-Ups 3Health News:Achieving realistic physical activity goals benefits RA patients 2Health News:Landmark law and neuroscience network expands at Vanderbilt 2Health News:Landmark law and neuroscience network expands at Vanderbilt 3
(Date:8/21/2014)... --  Memorial Hermann Health System and The University ... new partnership to provide a new level of specialized breast ... the greater Houston area. ... provider of professional breast radiology services for five of Memorial ... The Woodlands , Northeast, Southwest and ...
(Date:8/21/2014)... The spinal column is one of the most delicate and ... from the brain through the column control many key functions ... here can be life altering, and leave the victim in ... body. Though back injury and disease can have an intensely ... available to make things better than ever before. Laser ...
(Date:8/21/2014)...  Decision Resources Group finds that, for the ... and Mexico ... long-acting beta-agonist (LABA)- and long-acting muscarinic antagonist (LAMA)- ... severe cost/coverage constraints. Therefore, new brands of LABA/LAMA ... in these countries—which will considerably expand the chronic ...
Breaking Medicine Technology:Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3
... Calif., Nov. 10, 2010 ChemoCentryx, Inc., today ... the Annual American College of Rheumatology Meeting (ACR). ... is designed to target the receptor for the ... so-called anaphylatoxin that drives inflammatory responses associated with ...
... BLOOMINGTON, Minn., Nov. 10, 2010 A new ... Improvement (ICSI, www.icsi.org ), a nonprofit, health ... care community more than $28 million annually, as ... productivity. The initiative is the first ...
Cached Medicine Technology:ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR) 2ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR) 3ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR) 4Statewide Initiative Launched to Help Ensure Patients Receive Appropriate High-Tech Diagnostic Imaging Exams 2Statewide Initiative Launched to Help Ensure Patients Receive Appropriate High-Tech Diagnostic Imaging Exams 3Statewide Initiative Launched to Help Ensure Patients Receive Appropriate High-Tech Diagnostic Imaging Exams 4Statewide Initiative Launched to Help Ensure Patients Receive Appropriate High-Tech Diagnostic Imaging Exams 5
... Keeler Galilean loupes are ideal ... when increased magnification and a large ... loupes are laser aligned, lightweight and ... ,Fixed working distance and superior depth ...
U tip irrigation-aspiration cannual designed for manual removal of 12 oclock cortex. 23 gauge thin wall irrigation and aspiration lines for maximum aspiration capabilities. Polished finish. Overall l...
... stools come with five legs for ... 18" to 25" (total vertical travel ... rubber castors. Comfortable, durable and fire ... as standard, other colors available by ...
Anterior Stromal Puncture Cannula, 25 g. For treatment of recurrent corneal erosion. Overall length 24 mm. 5/box....
Medicine Products: